Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 15/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653153 | 0.86 | ALDH1A1 (0.54) | NAMPTALDH1A1LMNATSHRHTT | |
| SCHEMBL2653085 | 0.85 | NAMPT (0.39) | NAMPTJAK1ALDH1A1LMNATSHR | |
| SCHEMBL2653267 | 0.76 | CA2 (0.38) | — | |
| SCHEMBL2652919 | 0.76 | CNR2 (0.36) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2652827 | 0.75 | PTGS2 (0.42) | ALDH1A1LMNA | |
| SCHEMBL2653280 | 0.74 | PTGS2 (0.44) | ALDH1A1LMNA | |
| SCHEMBL2652798 | 0.71 | ALDH1A1 (0.42) | ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL1581938 | 0.70 | NAMPT (0.42) | NAMPTJAK1LMNATSHRHTT | |
| SCHEMBL2653863 | 0.70 | RAB9A (0.48) | ALDH1A1LMNATSHRHTTSMN1; SMN2 | |
| SCHEMBL2653840 | 0.69 | STAT3 (0.37) | ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113358792-A | HPLC content analysis method of medicinal substance | 北京亚宝生物药业有限公司 | 2021-09-07 | — | — | CN | claimed |
| CN-113267584-A | HPLC related substance analysis method for medicinal substance | 北京亚宝生物药业有限公司 | 2021-08-17 | — | — | CN | claimed |
| CN-113358792-A | HPLC content analysis method of medicinal substance | 北京亚宝生物药业有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-113267584-A | HPLC related substance analysis method for medicinal substance | 北京亚宝生物药业有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-1585739-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063179-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |